Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.6 USD | -5.51% | -5.26% | -6.25% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 216M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
Net cash position 2024 * | 164M | Net cash position 2025 * | 269M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3
x | P/E ratio 2025 * |
-2.48
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.76% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | -5.51% | ||
1 week | -5.26% | ||
Current month | +11.80% | ||
1 month | +15.02% | ||
3 months | +7.78% | ||
6 months | +52.54% | ||
Current year | -6.25% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 55 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 72 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 3.6 | -5.51% | 166,643 |
24-05-21 | 3.81 | -0.78% | 160,562 |
24-05-20 | 3.84 | +5.21% | 141,632 |
24-05-17 | 3.65 | -2.14% | 79,239 |
24-05-16 | 3.73 | -1.84% | 83,446 |
Delayed Quote Nasdaq, May 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.25% | 216M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.21% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- ABOS Stock